Abstract:Background: Almost a decade after its approval, sorafenib remains the only approved therapy for advanced hepatocellular carcinoma (HCC). Novel treatment is warranted for advanced HCC. Previous preclinical studies reported that inhibition of various cyclin dependent kinases (CDKs), whether cell cycle dependent or independent, showed activity against HCC. Dinaciclib is a potent inhibitor of CDK1, 2, 5, and 9 and has an acceptable safety profile in humans. We thus examined the efficacy of dinaciclib in HCC using preclinical models. Methods: In a panel of HCC cell lines with high Rb expression (HuH7, PLC5, HepG2, SK-Hep1, SNU387, SNU449, SNU426 and SNU475) and low Rb expression (Hep3B and HLE), dinaciclib was examined for its effect on cell viability. The impacts of dinaciclib on cell cycle distribution, apoptosis induction, and the expressions of phospho- (p-) Rb (the target of CDK1 and 2), p-ATM (the target of CDK5), c-myc, and p-RNA polymerase II (the target of CDK9) were explored in selected cell lines including HuH7 and PLC5. The in vivo efficacy of dinaciclib on HCC was tested in mouse xenografts of HuH7 cells implanted subcutaneously. Knockdown of various CDKs using RNA interference was conducted to explore the mechanisms of dinaciclib. Results: Dinaciclib showed potent anti-proliferative activities in all the tested HCC cell lines. The IC50s to dinaciclib by the MTT assay did not significantly differ between cell lines with high Rb expression (8.5 to 20.1 nM) and cell lines with low Rb expression (9.4 to 15.6 nM). After 48 hours of dinaciclib treatment, HuH7 and PLC5 cells showed G2/M arrest in a dose-dependent manner. Apoptosis assays including sub-G1 fraction analysis, DNA fragmentation detection, and cleaved PARP-1 confirmed the occurrence of apoptosis in HuH7 and PLC5 cells treated with dinaciclib. Dinaciclib at the concentration near the IC50 inhibited the phosphorylation of Rb, RNA polymerase II, and ATM in HuH7 and PLC5 cells; it also inhibited the expressions of multiple anti-apoptotic proteins including Mcl-1, XIAP, and survivin. In xenograft studies with HuH7 cells, mice receiving dinaciclib had a significantly slower tumor growth rate compared with mice receiving vehicles. The TUNEL assay showed that tumors treated with dinaciclib exhibited higher apoptosis activity. Mice tolerated the dinaciclib treatment well without significant body weight change. Knockdown of CDK 1, 2, 5, and 9 using RNA interference showed that CDK1 and CDK9 may contribute the most to the efficacy of dinaciclib. Conclusions: Composite knockdown of CDK 1, 2, 5, and 9 with dinaciclib showed potent activity against HCC. (This study was supported by Ministry of Science and Technology, Taiwan [MOST-103-2314-B-002-181-MY2, MOST-103-2314-B-002-090, MOST-103-2314-B-002-092]). Citation Format: Yi-Hsin Liang, Yu-Yun Shao, Yong-Shi Li, Hang Lin, Han-Yu Wang, Ann-Lii Cheng, Chih-Hung Hsu. Composite cyclin dependent kinase inhibition shows potent activity against hepatocellular carcinoma. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 2831.

Extracellular Vesicle Delivery of TRAIL Eradicates Resistant Tumor Growth in Combination with CDK Inhibition by Dinaciclib.

Overcoming acquired resistance to TRAIL by chemotherapeutic agents and calpain inhibitor I through distinct mechanisms.

Extracellular vesicle-mediated co-delivery of TRAIL and dinaciclib for targeted therapy of resistant tumors

Selective CDK9 Knockdown Sensitizes TRAIL Response by Suppression of Antiapoptotic Factors and NF-kappaB Pathway

EV-T synergizes with AZD5582 to overcome TRAIL resistance through concomitant suppression of cFLIP, MCL-1, and IAPs in hepatocarcinoma

Abstract 2831: Composite Cyclin Dependent Kinase Inhibition Shows Potent Activity Against Hepatocellular Carcinoma

Novel Insights into the Synergistic Interaction of a Thioredoxin Reductase Inhibitor and TRAIL: the Activation of the ASK1-ERK-Sp1 Pathway

Cisplatin enhances the antitumor effect of tumor necrosis factor-related apoptosis-inducing ligand gene therapy via recruitment of the mitochondria-dependent death signaling pathway

TRAIL delivery by MSC-derived extracellular vesicles is an effective anticancer therapy

2-Tellurium-bridged Β-Cyclodextrin, a Thioredoxin Reductase Inhibitor, Sensitizes Human Breast Cancer Cells to TRAIL-induced Apoptosis Through DR5 Induction and NF-κB Suppression.

Dinaciclib Prolongs Survival in the LSL-KrasG12D/+ ; LSL-Trp53R172H/+ ; Pdx-1-Cre (KPC) Transgenic Murine Models of Pancreatic Ductal Adenocarcinoma.

TRIAL-based Combination Therapies in Cancers

CCT327 enhances TRAIL-induced apoptosis through the induction of death receptors and downregulation of cell survival proteins in TRAIL-resistant human leukemia cells.

Decitabine Enhances the Tumoricidal Potential of TRAIL Via the Epigenetic Regulation of Death Receptor 4 in Gastric Cancer

Combination Of Trail And Actinomycin D Liposomes Enhances Antitumor Effect In Non-Small Cell Lung Cancer

Synthetic lethality of cyclin-dependent kinase inhibitor Dinaciclib with VHL-deficiency allows for selective targeting of clear cell renal cell carcinoma

Rational Combination Therapy for Melanoma with Dinaciclib by Targeting BAK-Dependent Cell Death

Tumor Necrosis Factor-Related Apoptosis Inducing Ligand Overexpression and Taxol Treatment Suppresses the Growth of Cervical Cancer Cells in Vitro and in Vivo

Enhancement of Anti-Tumor Properties of Trail by Targeted Delivery to the Tumor Neovasculature

BAY61-3606 Potentiates the Anti-Tumor Effects of TRAIL Against Colon Cancer Through Up-Regulating DR4 and Down-Regulating NF-κB.

Trail-Armed Er Nanosomes Induce Drastically Enhanced Apoptosis In Resistant Tumor In Combination With The Antagonist Of Iaps (Azd5582)